miércoles, 17 de mayo de 2017

Journal for ImmunoTherapy of Cancer | Basic Tumor Immunology

Journal for ImmunoTherapy of Cancer | Basic Tumor Immunology

Biomed Central

Journal for ImmunoTherapy of Cancer

JITC logo

Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)

Basic Tumor Immunology

Section edited by Cornelis J.M. Melief, MD, PhD
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.


    A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

    Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. T...
    Dina Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, Andrew Kaiser, Boro Dropulic and Rimas J. Orentas
    Journal for ImmunoTherapy of Cancer 2017 5:42
    Published on: 16 May 2017

    Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation

    Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with...
    Mohanad H. Nada, Hong Wang, Grefachew Workalemahu, Yoshimasa Tanaka and Craig T. Morita
    Journal for ImmunoTherapy of Cancer 2017 5:9
    Published on: 21 February 2017

    Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model

    Although therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine...
    James T. Gordy, Kun Luo, Hong Zhang, Arya Biragyn and Richard B. Markham
    Journal for ImmunoTherapy of Cancer 2016 4:96
    Published on: 20 December 2016

    Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases

    Tumors avoid destruction by cytotoxic T cells (CTL) and natural killer (NK) cells by downregulation of classical human leukocyte antigens (HLA) and overexpression of non-classical HLA. This is the first study ...
    Debbie M. Ferns, A. Marijne Heeren, Sanne Samuels, Maaike C. G. Bleeker, Tanja D. de Gruijl, Gemma G. Kenter and Ekaterina S. Jordanova
    Journal for ImmunoTherapy of Cancer 2016 4:78
    Published on: 15 November 2016

    Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide

    Future cancer immunotherapies will combine multiple treatments to generate functional immune responses to cancer antigens through synergistic, multi-modal mechanisms. In this study we explored the combination ...
    Genevieve M. Weir, Olga Hrytsenko, Tara Quinton, Neil L. Berinstein, Marianne M. Stanford and Marc Mansour
    Journal for ImmunoTherapy of Cancer 2016 4:68
    Published on: 18 October 2016

    Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape

    Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known abou...
    Itsaso Montalbán del Barrio, Cornelia Penski, Laura Schlahsa, Roland G. Stein, Joachim Diessner, Achim Wöckel, Johannes Dietl, Manfred B. Lutz, Michel Mittelbronn, Jörg Wischhusen and Sebastian F. M. Häusler
    Journal for ImmunoTherapy of Cancer 2016 4:49
    Published on: 16 August 2016

    Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5

    Therapeutic resistance and tumor recurrence are two major hurdles in the treatment of pancreatic ductal adenocarcinoma. Recent findings suggest that both of these attributes are associated with a small subset ...
    Jason W.-L. Eng, Thomas A. Mace, Rohit Sharma, Danielle Y. F. Twum, Peng Peng, John F. Gibbs, Rosemarie Pitoniak, Chelsey B. Reed, Scott I. Abrams, Elizabeth A. Repasky and Bonnie L. Hylander
    Journal for ImmunoTherapy of Cancer 2016 4:33
    Published on: 21 June 2016

    Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient

    Adoptive T-cell based immunotherapies constitute a promising approach to treat cancer, however, a major problem is to obtain effective and long-lasting anti-tumor responses. Lack of response may be due to insu...
    Imran Siddiqui, Marco Erreni, Mandy van Brakel, Reno Debets and Paola Allavena
    Journal for ImmunoTherapy of Cancer 2016 4:21
    Published on: 19 April 2016

    Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant

    Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein with a broad tissue distribution. It can be intracellular, membrane-bound, or secreted, and it exists as a monomer or hetero...
    Brian M. Andersen, Junzhe Xia, Alan L. Epstein, John R. Ohlfest, Wei Chen, Bruce R. Blazar, Christopher A. Pennell and Michael R. Olin
    Journal for ImmunoTherapy of Cancer 2016 4:11
    Published on: 16 February 2016

    Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma

    A current focus in cancer treatment is to broaden responses to immunotherapy. One reason these therapies may prove inadequate is that T lymphocytes fail to recognize the tumor due to differences in immunogenic...
    Katherine Woods, Ashley J. Knights, Matthew Anaka, Ralf B. Schittenhelm, Anthony W. Purcell, Andreas Behren and Jonathan Cebon
    Journal for ImmunoTherapy of Cancer 2016 4:10
    Published on: 16 February 2016

    Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

    Lymphodepletion enhances adoptive T cell transfer (ACT) therapy by activating the innate immune system via microbes released from the radiation-injured gut. Microbial components, such as LPS, are key mediators...
    Michelle H. Nelson, Jacob S. Bowers, Stefanie R. Bailey, Marshall A. Diven, Caroline W. Fugle, Andrew D. M. Kaiser, Claudia Wrzesinski, Bei Liu, Nicholas P. Restifo and Chrystal M. Paulos
    Journal for ImmunoTherapy of Cancer 2016 4:6
    Published on: 16 February 2016

    Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors

    Adoptive cell transfer of tumor-specific T lymphocytes (T cells) is proving to be an effective strategy for treating established tumors in cancer patients. One method of generating these cells is accomplished ...
    Joanne A. Hammill, Heather VanSeggelen, Christopher W. Helsen, Galina F. Denisova, Carole Evelegh, Daniela G. M. Tantalo, Jennifer D. Bassett and Jonathan L. Bramson
    Journal for ImmunoTherapy of Cancer 2015 3:55
    Published on: 15 December 2015

    Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

    Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastas...
    Anders Olsson, Jessica Nakhlé, Anette Sundstedt, Pascale Plas, Anne-Laure Bauchet, Valérie Pierron, Luce Bruetschy, Adnan Deronic, Marie Törngren, David Liberg, Fabien Schmidlin and Tomas Leanderson
    Journal for ImmunoTherapy of Cancer 2015 3:53
    Published on: 15 December 2015

    Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

    Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with immunostimulatory monoclonal antibodies has been successful in cancer immunotherapy. However, targeting of CD27 with a mAb is a relat...
    Venky Ramakrishna, Karuna Sundarapandiyan, Biwei Zhao, Max Bylesjo, Henry C. Marsh and Tibor Keler
    Journal for ImmunoTherapy of Cancer 2015 3:37
    Published on: 18 August 2015

    Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer

    Ovarian cancer is immunogenic and residual tumor volume after surgery is known to be prognostic. Ovarian cancer often follows a recurring-remitting course and microscopic disease states may present ideal oppor...
    John B Liao, Kelsie J Ovenell, Erin E M Curtis, Denise L Cecil, Marlese R Koehnlein, Lauren R Rastetter, Ekram A Gad and Mary L Disis
    Journal for ImmunoTherapy of Cancer 2015 3:16
    Published on: 19 May 2015

    NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade

    Melanoma is one of the few types of cancer with an increasing annual incidence. While a number of immunotherapies for melanoma have been associated with significant clinical benefit, including high-dose IL-2 a...
    Frederick J Kohlhapp, Joseph R Broucek, Tasha Hughes, Erica J Huelsmann, Jevgenijs Lusciks, Janet P Zayas, Hubert Dolubizno, Vidyaratna A Fleetwood, Alisa Grin, Graham E Hill, Joseph L Poshepny, Arman Nabatiyan, Carl E Ruby, Joshua D Snook, Jai S Rudra, Jason M Schenkel…
    Journal for ImmunoTherapy of Cancer 2015 3:18
    Published on: 19 May 2015

    T cell-NF-κB activation is required for tumor control in vivo

    T cells have the capacity to eliminate tumors but the signaling pathways by which they do so are incompletely understood. T cell priming requires activation of the transcription factors AP-1, NFAT and NF-κB do...
    Sarah E Barnes, Ying Wang, Luqiu Chen, Luciana L Molinero, Thomas F Gajewski, Cesar Evaristo and Maria-Luisa Alegre
    Journal for ImmunoTherapy of Cancer 2015 3:1
    Published on: 20 January 2015

    Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

    Multiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable disease. Successful treatments will likely require mul...
    Weiqing Jing, Jill A Gershan, James Weber, Dominique Tlomak, Laura McOlash, Catherine Sabatos-Peyton and Bryon D Johnson
    Journal for ImmunoTherapy of Cancer 2015 3:2
    Published on: 20 January 2015

    iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine

    Therapeutic cancer vaccines aim to boost the natural immunity against transformed cancer cells, and a series of adjuvants and co-stimulatory molecules have been proposed to enhance the immune response against ...
    Stéphanie Corgnac, Rachel Perret, Lianjun Zhang, Jean-Pierre Mach, Pedro Romero and Alena Donda
    Journal for ImmunoTherapy of Cancer 2014 2:39
    Published on: 18 November 2014

No hay comentarios:

Publicar un comentario